|
Indian pharmaceutical market records healthy 5-year CAGR of over 10 per cent
|
|
Our Bureau, Chennai
November 08 , 2025
|
|
|
The Indian Pharmaceutical Market (IPM) has demonstrated remarkable resilience and growth momentum, recording a robust five-year Compound Annual Growth Rate (CAGR) of approximately 10.02 per cent for the period ending September 2025.
This finding, highlighted in the latest IQVIA Market Feedback Report (MFR), solidifies the sector’s standing as a crucial driver of the Indian economy and a consistent performer for investors. Despite global economic fluctuations, the domestic market has consistently expanded, adding significant value over the half-decade review.
The sustained double-digit growth rate is a testament to several factors, including increased health awareness, expanded access to healthcare services, and a stable regulatory environment encouraging innovation. This long-term trend underscores the fundamental, non-cyclical demand for pharmaceutical products in India, driven by both demographic factors like a growing and aging population and the increasing prevalence of lifestyle diseases. Furthermore, the report indicates that the monthly growth rate for September 2025 alone clocked in at a healthy 6.1 percent, showing that the overall market remains on an upward trajectory.
A deeper dive into the data reveals that this performance is not uniform across all segments, with the chronic segment playing an increasingly influential role. The IQVIA MFR points out that long-term therapies for conditions like cardiovascular diseases, diabetes, and central nervous system disorders have consistently outperformed the acute segment, which focuses on short-term treatments like anti-infectives and pain relief. This differential growth highlights a key shift in the structure of the market toward managing long-term health needs.
In terms of market leadership, the report confirms the enduring strength of the country's pharmaceutical giants. Sun Pharma maintained its commanding presence, securing the number one rank in MAT (Moving Annual Total) sales, followed closely by multinational Abbott and domestic powerhouse Cipla. Their consistent performance and diversified product portfolios have allowed these firms to capitalize most effectively on the broader market expansion.
The success story is also mirrored in the therapeutic classes, where essential drugs continue to dominate. Cardiac therapies and anti-infectives emerged as the largest contributors to overall sales value, reflecting the significant disease burden in these areas. However, the most explosive growth was witnessed in the antineoplast/immunomodulators class, which focuses on cancer and immune system treatments, recording an astonishing monthly growth of 24.6 percent in September 2025, signalling substantial investment and innovation in high-value, complex therapies.
Beyond established market players and segments, the report also detailed the energy injected by new product introductions. The twelve months leading up to September 2025 saw the launch of 3,154 new brands, collectively generating a sale of Rs.1,860.8 crore. This robust level of new activity confirms the industry's commitment to bringing novel formulations and products to the Indian populace, sustaining the market’s dynamism.
Ultimately, the IQVIA MFR provides a highly positive outlook for the Indian Pharmaceutical Market, confirming its role as a high-growth sector. The sustained CAGR of over 10 per cent not only reflects past success but sets an optimistic benchmark for future performance, driven by rising chronic disease management, consistent innovation, and the strategic positioning of the country’s leading pharmaceutical companies.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|